Single-cell transcriptome landscape in hepatocellular carcinoma of BALB/C mice after azvudine treatment

Hepatocellular carcinoma is the sixth most common malignant tumor in the world, but there is a lack of effective drugs for the treatment of HCC, so it is urgent to find new treatment strategies. Azvudine is the world's first dual-target innovative anti-AIDS drug, which can selectively enter CD4+T lymphocytes to exert immunomodulatory effects. In the early stage, we found through a retrospective cohort study that azivudine can significantly reduce all-cause mortality and the incidence of composite disease progression in COVID-19 patients with tumors compared with COVID-19 patients without tumors. Therefore, we performed single-cell RNA sequencing on tumor tissues of BALB/C mice treated with azivudine or treated with vehicle to reveal the changes in the tumor microenvironment of azivudine against liver cancer.